

Brazikumab

| | |
|-----------|---|
| Cat. No.: | HY-P99485 |
| CAS No.: | 1610353-18-8 |
| Target: | Interleukin Related |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a K_D of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease ^[1] . |
| IC ₅₀ & Target | IL-23 0.138 nM (Kd) |
| In Vitro | Brazikumab inhibits the binding of both recombinant and native IL-23 to its receptors stably expressed in COS cells with IC ₅₀ s of 188 and 284 pM, respectively ^[1] . Brazikumab inhibits the production of IFN- γ in NK cells stimulated by human native or recombinant IL-23 (in association with IL-18) with IC ₅₀ s of 238 and 93 pM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400.
- [2]. Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA